Purpose The development of multidrug resistance (MDR) is one of the major limitations in the treatment of cancer. Induction of P-glycoprotein (Pgp) has been regarded as one of the main mechanisms underlying anticancer drug-induced MDR. Since the induction of Pgp is (in part) regulated by the pregnane X receptor (PXR), the ability of several widely used anticancer drugs to activate PXR-mediated Pgp induction was investigated. Methods A Pgp-reporter gene assay was employed to determine the ability of a panel of widely used anticancer drugs to induce Pgp. To further assess whether PXR could be involved in the induction of Pgp by anticancer drugs, Pgp protein expression after treatment with the anticancer drugs was determined in both wild-type and PXR-knocked down LS180 cells. Furthermore, the eVect of the anticancer drugs on the intracellular accumulation of the Pgp-probes rhodamine 123 and doxorubicin was determined.
Introduction
A major drawback in the successful treatment of advanced malignancies is the development of multidrug resistance (MDR). One of the main causes by which cancer cells acquire the multidrug resistant phenotype in response to chemotherapy is the induction of ATP-binding cassette (ABC) drug eZux transporter proteins. An important mediator of MDR that has been associated with poor treatment response in various malignancies is the ABC-family member P-glycoprotein (Pgp; ABCB1; MDR1) [1] [2] [3] . Pgp is a transmembrane protein that protects the cell from xenobiotic stress by facilitating the extrusion of a broad spectrum of substrates, including anticancer drugs such as the anthracyclines, epipodophyllotoxins, Vinca alkaloids and taxanes. As a consequence, induction of Pgp aVects the eYcacy of these agents by decreasing their intracellular accumulation in cancer cells.
The pregnane X receptor (PXR; NR1I2) has been identiWed as a major regulator of Pgp induction [4] , and, apart from expression in the liver and small intestines, has been shown to be expressed in several cancerous tissues such as breast, colon, bone, prostate and endometrial cancers [5] [6] [7] [8] [9] . PXR is a very promiscuous receptor that is activated by a wide variety of structurally unrelated ligands including rifampicin, hyperforin and the anticancer drug paclitaxel. Due to the promiscuity of PXR, possibly other widely used anticancer drugs could also activate PXRmediated Pgp induction, and as a consequence induce MDR in cancer cells.
In the current study, a panel of widely used anticancer drugs was evaluated for their ability to activate PXRmediated Pgp induction in the colon adenocarcinomaderived cell line LS180. In addition, the eVect of PXR activation on the intracellular accumulation of Pgp substrates was determined. Our results demonstrate that several widely used anticancer drugs can activate PXR-mediated induction of Pgp and as a consequence decrease the intracellular accumulation of Pgp substrates. In addition, evidence is presented that the cytotoxic activity of doxorubicin is reduced when cells are pretreated with the PXR activator rifampicin.
Materials and methods

Materials
All cell culture media and supplements were purchased from Invitrogen (Breda, The Netherlands). Carboplatin, ifosfamide, tamoxifen citrate and etoposide were obtained from Axxora (San Diego, CA, USA). Zosuquidar (LY335979) was obtained through Kanisa Pharmaceuticals Inc. (Irvine, CA, USA). All other chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Plasmids
The pGL3-MDR1 (p-10224) luciferase reporter construct was generously provided by Dr. Oliver Burk (Institute of Clinical Pharmacology, Eberhard-Karls University, Tübingen, Germany). The pCDG-hPXR expression vector was generously provided by Dr. Ron Evans (Salk institute for biological studies, La Jolla, CA, USA). The pRL-TK control plasmid was obtained from Promega (Madison, WI, USA). Plasmids were checked by enzyme restriction and agarose gel electrophoresis and puriWed using Promega's Pureyield Midi-prep (Madison, WI, USA) according to the instructions of the manufacturer.
Cell culture
The human colon adenocarcinoma-derived cell line LS180 was purchased from the ATCC (Manassas, VA, USA). The cell-line was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (with 25 mM HEPES and L-glutamine, supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 g/ml streptomycin), at 37°C under a humidiWed atmosphere of 5% CO 2 .
Cell viability
Cell viability was after 48 h, and the anticancer drug treatment was assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-assay.
Pgp reporter gene assay
The Pgp reporter gene assay was performed in a similar manner as described previously [10] . In brief, LS180 cells were transfected with a pCDG-hPXR expression vector, a pGL3-MDR1 luciferase reporter construct, and a pRL-TK control plasmid for 24 h. After transfection, the transiently transfected LS180 cells were treated with the highest non-toxic concentration of each anticancer drug. After 48 h incubation, the reporter activity was determined. 
RNA interference of PXR
The siRNA sequence targeting human PXR (sense: cguuuguucgcuuccugagtt; antisense: cucaggaagcgaacaaacgtg) and the negative control, which consisted of a non-complementary sequence, were purchased from Ambion (Austin, TX, USA). LS180 cells were reversely transfected 48 h prior to the Pgp induction experiment with 50 nM siRNA PXR or 50 nM negative control siRNA using Lipofectamine RNAi Max (Invitrogen, Breda, The Netherlands). Subsequently, PXR knockdown and control LS180 cells were treated with diVerent anticancer drugs for 48 h.
Immunoblot analysis
After 48 h of culture, cells were washed with phosphatebuVered saline (PBS), and lysed in 1 ml/well MilliQ water that contained protease inhibitors (Roche, Basal, Switzerland). The lysate was centrifuged (5,000 rpm, 5 min, 4°C), and the remaining pellet was resuspended in 100 L RIPA buVer. The lysate was centrifuged (10,000 rpm, 5 min, 4°C) and the supernatant was transferred to a new collection tube. Protein concentrations were determined by a Pierce BCA protein assay (Pierce, Rockford, IL, USA). Ten micrograms of total protein was separated by SDSpolyacrylamide gel electrophoresis using NuPage novex 4-12% bis-tris gradient gels (Invitrogen, Breda, The Netherlands). Proteins were electroblotted onto Immobilon P membranes (Millipore, Bedford, MA, USA). After blocking (1 h at RT) in 3% BSA in tris-buVered saline containing 0.1% Tween-20, the membranes were incubated overnight at 4°C with a murine monoclonal anti-Pgp primary antibody (C219, 1:500; Abcam, Cambridge, UK) followed by incubation with a goat anti-mouse IgG coupled to horse radish peroxidase (HRP) secondary antibody (1:1,000; ImmunoPure Peroxidase Conjugated Goat anti-Mouse IgG (H + L); Pierce, Rockford, IL, USA). -actin (1:10,000; AC-15; Abcam, Cambridge, UK) was used as a loading control. The proteins were visualized by a chemiluminescence-based detection reagent (SuperSignal West Femto; Pierce, Rockford, IL, USA), and the intensities of the Pgp bands were determined on a Gel Doc XRS Imaging system with Quantity One analysis software (Bio-Rad, Hercules, CA, USA). The ratio of the Pgp signal and the -actin signal were indicative for Pgp protein expression.
Rhodamine 123 accumulation assay
The eZux activity of Pgp was determined by measuring the accumulation of the Xuorescent Pgp probe rhodamine 123 as described by Collett et al. [11] . In brief, LS180 cells were pretreated with the anticancer drugs as described earlier. After 48 h, the cells were washed with Hank's Balanced Salt Solution (HBSS) and incubated at 37°C for 1 h with rhodamine 123 (10 M) in the presence or absence of the Pgp-speciWc inhibitor zosuquidar (LY335979; 5 M; [12] ) in phenol red-free RPMI medium. After washing thrice with ice-cold HBSS, the cells were lysed with Triton X-100 (0.1%) in MilliQ water (Millipore, Bedford, MA, USA). The ratio of intracellular rhodamine 123 concentrations in the absence and presence of 5 M zosuquidar is indicative for the eZux activity of Pgp.
Doxorubicin accumulation LS180 cells (0.5 £ 10 6 c/well) were plated in a 24-well plate. After a 48 h incubation with 0.1% DMSO or 10 M rifampicin, cells were treated with 5 M doxorubicin for 90 min. Cells were washed thrice with ice-cold PBS, lysed in 250 l MilliQ water, and homogenized by ultrasoniWcation Labsonic P (Braun; cycle 0.2 min en Amplitude 60%). Hundred microliters of the homogenate was processed for HPLC analysis. Daunorubicin was used as an internal standard. The samples and standard solutions were prepared as described by van Asperen et al. [13] .
Doxorubicin HPLC analysis
Doxorubicin was quantiWed using a method as previously described by DeGregorio et al. [14] . In brief, samples were eluted isocratically with a mobile phase that consisted of 28% acetonitrile in 60 mM phosphoric acid. A Waters Symmetry C18 3.5 M, 4.6 mm £ 100 mm reverse-phase column was used. Fluorescence was detected using a JASCO FP-920 Xuorometer (excitation: 455 nm; emission: 550 nm), Shimadzu LC10AT-VP pumps and a Shimadzu SCL10A-VP controller. The Xow rate was set at 1.0 ml/ min. Doxorubicin and daunorubicin retention times were 2.38 and 5.01 min, respectively. A standard curve of doxorubicin (0.08, 0.4, 2, 10 and 50 M) was prepared in milliQ water.
Doxorubicin cytotoxicity assay LS180 cells were plated (2 £ 10 4 cells/well; 96 well plates) and treated with 10 M rifampicin or 0.1% DMSO. Following 72 h incubation, cells were exposed to doxorubicin (serially diluted 0-20 M; dilution factor 2). Cell viability after 48 h doxorubicin exposure was assessed using a neutral red assay [15] .
Statistical analysis
One-way ANOVA with Bonferroni post hoc testing was performed for statistical comparison of the obtained Pgp reporter gene and activity results and considered statistically signiWcant when P < 0.05. All statistical calculations were done in SPSS (v14, SPSS Inc. Chicago, IL, USA).
Results
Cell viability
Cell viability was assessed after 48 h treatment with diVerent concentrations of the anticancer drugs. As shown in Fig. 1 , the anticancer drugs did not signiWcantly aVect the LS180 cell viability at the concentrations used, while the doxorubicin (10 M) did aVect cell viability.
PXR-mediated Pgp reporter activation by anticancer drugs
The ability of widely used anticancer drugs to induce the expression of Pgp via activation of PXR was determined. LS180 cells were transfected with a Pgp reporter construct as well as a PXR expression plasmid. Treatment of the transiently transfected LS180 cells with cyclophosphamide, ifosfamide, docetaxel, paclitaxel, Xutamide, and tamoxifen resulted in dose-dependent increases in Pgp reporter activity, while exposure to diVerent concentrations of carboplatin and etoposide did not increase PXR-mediated Pgp reporter activity (Fig. 2) . As a control, the same compounds were tested in LS180 cells that were only transfected with the Pgp reporter gene construct without co-transfection of a PXR expression plasmid. In these cells, none of the compounds was able to activate Pgp reporter activity (results not shown).
Induction of Pgp protein expression
To evaluate whether Pgp reporter activation is predictive for Pgp protein induction, the eVect of the anticancer drugs on the protein expression levels of Pgp after 48 h treatment in LS180 cells was determined. As shown in Fig. 3 , all compounds that were shown to activate PXR-mediated Pgp reporter activity (vincristine, tamoxifen, vinblastine, doce- 
Rhodamine 123 accumulation assay
To assess whether PXR-mediated Pgp induction aVects the accumulation of Pgp substrates, the transport activity of Pgp was analyzed using a rhodamine 123 accumulation assay. Following 48 h pretreatment with the anticancer drugs, cells were exposed to rhodamine 123 in the absence or presence of the Pgp-speciWc inhibitor zosuquidar (LY335979; IC50 = 4nM) [16] . The ratio between the intracellular Xuorescence of rhodamine 123 in the presence and absence of zosuquidar is indicative for the Pgp transport activity in the treated LS180 cells [11] . As shown in Fig. 4 , rhodamine 123 accumulation corresponds with Pgp protein expression data; low cellular rhodamine 123 accumulation was observed for paclitaxel, docetaxel and Xutamide, which were shown to induce Pgp protein expression, 
EVect of PXR activation on doxorubicin cytotoxicity
To study whether activation of PXR aVects the eYcacy of a cytotoxic Pgp substrate, the eVect of PXR activation on the cytotoxicity of doxorubicin in LS180 was assessed. Therefore, prior to doxorubicin exposure, LS180 cells were pretreated with the prototypical PXR agonist 10 M rifampicin or 0.1% DMSO (solvent) for 48 h. As shown in Fig. 5a , rifampicin pretreatment aVects the intracellular accumulation of doxorubicin. To determine whether reduced accumulation of doxorubicin also aVects the eYcacy of this agent, rifampicin-or solvent-pretreated cells were exposed to diVerent doxorubicin concentrations (ranging from 0.3 to 20 M; dilution factor 2). As shown in Fig. 5b , following doxorubicin exposure cell viability was signiWcantly (P < 0.05) higher in the rifampicin-pretreated cells (IC 50 = 2.5 M) compared to the solvent (0.1% DMSO) pretreated cells (IC 50 = 1.5 M). This indicates that PXR activation indeed can reduce the activity of cytotoxic Pgp substrates as a result of decreased intracellular accumulation.
Discussion
The development of MDR in response to anticancer treatment is a major problem in the clinic. Since induction of Pgp is one of the main mechanisms underlying acquired MDR, we evaluated whether several widely used anticancer drugs can induce Pgp expression via activation of PXR, a nuclear receptor that is increasingly associated with acquired MDR [9, 17] . Indeed, several anticancer drugs (vincristine, vinblastine, cyclophosphamide, ifosfamide, docetaxel, Xutamide and tamoxifen) were shown to increase Pgp reporter activity in cells co-transfected with a PXR expression plasmid. In accordance, the same anticancer drugs induced Pgp protein expression in LS180 cells. However, when PXR was knocked down in these cells treatment with the indicated anticancer drugs did not result in Pgp protein induction. Together these results indicate that PXR plays a substantial role in anticancer drug-related Pgp induction.
Furthermore, since Pgp is a drug eZux transporter that is involved in the extrusion of a wide variety of substrates from the cell, the eVect of Pgp protein induction following treatment with the indicated anticancer drugs on the intracellular accumulation of Pgp substrates was evaluated. Docetaxel, Xutamide, paclitaxel and the positive control rifampicin that induced Pgp protein expression indeed aVected the intracellular accumulation of the Pgp substrate rhodamine 123. In addition, carboplatin and etoposide, which had no eVect on Pgp protein expression, did not aVect rhodamine 123 accumulation. However, tamoxifen was shown to activate PXR-mediated Pgp protein induction, but did not aVect the accumulation of rhodamine 123. This can be explained by the fact that tamoxifen is also a known inhibitor of Pgp and thus prevents the Pgp-mediated extrusion of rhodamine 123 [18] . The observed discrepancy between the Pgp protein expression and Pgp functionality after treatment with the Vinca alkaloids is diYcult to explain and requires further investigation. Since activation of PXR by anticancer drugs was shown to aVect the accumulation of Pgp substrates, we further assessed whether PXR activation could also attenuate the cytotoxic eVects of doxorubicin, a known cytotoxic Pgp substrate. However, to avoid potential pharmacodynamic interactions between the selected anticancer drugs and doxorubicin that could lead to increased cytotoxicity, we chose to pretreat the cells with the prototypical PXR agonist rifampicin. Indeed, pretreatment of LS180 cells with rifampicin decreased the intracellular accumulation of the cytotoxic Pgp substrate doxorubicin and additionally signiWcantly reduced the cytotoxic eYcacy of this agent. These results indicate that activation of PXR-mediated Pgp induction by anticancer drugs can underlie the development of acquired resistance. This is further supported by studies of Chen et al. [9] and Gupta et al. [17] , who have shown that activation of PXR promotes the multidrug resistant phenotype of prostate and ovarian cancer cell lines, respectively.
Since Pgp is co-expressed with PXR in important barrier tissues, such as the intestines and the liver, activation of PXR-mediated Pgp induction could aVect the pharmacokinetic proWle of (oral) anticancer drugs. Indeed, drug-drug interactions as a result of PXR-mediated Pgp induction have been reported. For instance, intake of St. John's wort, which contains the PXR agonist hyperforin, by healthy volunteers resulted in a 1.9-fold increase in the oral clearance of the Pgp substrate fexofenadine [19] , while rifampicin pretreatment resulted in a 1.3-to 5.3-fold increase in the oral clearance of fexofenadine [20] . In the same manner, anticancer drugs that activate PXR might aVect their own pharmacokinetics, but also that of other concomitantly administered (anticancer) drugs.
In conclusion, several widely used anticancer drugs were shown to activate PXR-mediated Pgp induction, and as a result aVect the intracellular accumulation and cytotoxic activity of Pgp substrates.
